

# Apostle Dundas Global Equity Fund – Class C



Australian PDS and New Zealand Clients – ARSN 093 116 771 APIR ETL0438AU

Monthly Report – December 2025

## Investment Objective

- The target is to exceed the MSCI All Country World ex Australia Index by 2.5% p.a. after all fees and expenses on a rolling 5-year basis.
- Long term dividend growth and capital appreciation.
- To achieve lower volatility than the benchmark.

## Investment Firm

Established in 2010, Dundas Global Investors (“Dundas”) is an independent Investment Management firm based in Edinburgh that manages a single investment strategy, global equities.

Dundas can best be categorised as Quality Growth, with a focus on companies with strong and sustainable returns on equity and a growing dividend stream.

## Key Advantages

- Pro-active management of both components of total return (capital and dividends)
- Fee minimisation and alignment of incentives
- Lower cost base
- Enhanced research that capitalises on technology

## Investment Style

Dundas invests for capital and income growth. The team uses fundamental, bottom-up research to find companies capable of real long-term wealth generation that will lead to sustainable capital and dividend growth. While dividends are an important part of the investment proposition, Dundas places greater emphasis on future income streams as opposed to current payout ratios. The resulting portfolio is globally diversified, has an average holding period of more than five years, with satisfactory upside and good downside capture statistics.

## Characteristics

Unit Price (NAV)	AUD\$2.5484
Fund Size (AUD)	AUD\$2,726.86M
Tax Losses Available (As at last distribution period)	AUD\$215.36M
Portfolio Inception Date	August 2012
Inception Date - Class C	June 2015
Companies in Portfolio	Targeting 50-65 holdings
Sub-Investment Manager	Dundas Global Investors
Management Fee	0.90% p.a. (inc. GST and RITC)
Buy/Sell Spread	15/15 (bps)
Portfolio Management Team	Alan McFarlane – Chair David Keir – Managing Partner James Curry – Partner Gavin Harvie – Partner Andrew Brown – Partner
Responsible Entity	K2 Asset Management Ltd
Custodian/Registry	State Street Australia Limited

Source: Dundas Global Investors as at 31/12/25

## Performance

Return (%)	1 mth	3 mth	1 yr	3 yr (p.a.)	5 yr (p.a.)	7 yr (p.a.)	10 yr (p.a.)	Incep (p.a.)
Total (gross)	-1.16	2.11	4.43	15.01	11.02	14.04	12.61	11.44
Total (net)	-1.24	1.88	3.50	13.99	10.03	13.03	11.60	10.44
Relative (gross)*	-0.50	-0.63	-9.66	-6.70	-3.62	-0.93	-0.18	-0.46
Relative (net)**	-0.58	-0.86	-10.59	-7.72	-4.61	-1.94	-1.19	-1.45

Source: State Street Performance & Analytics Australia. Fund performance calculated using exit prices and shown on a total return basis (net dividends reinvested). Performance inception date is 4th June 2015. \*Relative (gross) calculated as the difference between the Fund's gross (of fees) return and that of the Solactive GBS Global Markets ex Australia Large & Mid Cap AUD Index \*\*Relative (Net) calculated as the difference between the Fund's net (of fees) return and that of the Solactive GBS Global Markets ex Australia Large & Mid Cap AUD Index. Past performance is not a reliable indicator of future performance.

## Portfolio Characteristics

No of Holdings	51
Dividend Yield	1.31
Turnover* (last 12 months)	21.70%
Price/Earnings	30.13
Price/Cash Flow	22.05
Price/Book Value	8.04x
Beta (ex-ante)	0.86
Average market capitalisation	\$293.86bn
Median market capitalisation	\$104.04bn
Tracking error (1 year)	5.08

\*Turnover calculated as ((Purchases + Sales)/2) / average assets during the period. Source: Dundas Global Investors and Apostle Funds Management as at 31/12/25

## Market Cap Exposure (% weight by capital)

Range	Fund
>US\$ 500bn	15.90
US\$ 100 - 500bn	44.68
US\$ 50 - 100bn	9.06
US\$ 10 - 50bn	28.33
US\$ 2 - 10bn	0.57

Source: Dundas Global Investors as at 31/12/25

## Top Ten Holdings by Capital (% weight)

Stock	Fund	Active Weight*
Alphabet	4.12	2.28
Microsoft	3.94	0.19
WR Berkley	3.64	3.62
TSMC	3.54	3.54
Amphenol	3.34	3.15
Applied Materials	3.15	2.88
American Express	3.12	2.91
Essilorluxottica	3.03	2.92
Visa	2.80	2.19
Thermo Fisher Scientific	2.59	2.34
TOTAL	33.26	26.02

\*Active Weight relative to the Index. Source: Dundas Global Investors and Apostle Funds Management as at 31/12/25

## Regional Allocation (%)

Country	Fund	Active Weight*
United States	57.55	-4.38
France	11.51	9.37
Switzerland	4.44	2.23
Taiwan	3.54	1.01
Hong Kong	3.44	2.43
Denmark	3.11	2.66
Sweden	2.89	1.99
United Kingdom	2.46	-0.85
Netherlands	2.36	1.17
Singapore	2.36	1.92
Germany	2.13	0.04
Japan	1.49	-4.27
India	1.26	-0.52
Other Countries	0.00	0.00

\*Active Weight relative to the Index. Source: Dundas Global Investors and Apostle Funds Management as at 31/12/25

## Sector Exposure (%)

Sector	Fund	Active Weight*
Information Technology	27.15	-0.29
Financials	25.88	9.00
Health Care	20.86	11.89
Industrials	8.46	-2.58
Consumer Discretionary	6.07	-4.46
Communication Services	4.12	-4.96
Materials	3.58	0.12
Consumer Staples	2.42	-2.70
Energy	0.00	-3.39
Real Estate	0.00	-1.62
Utilities	0.00	-2.47
Cash	1.46	1.46

\*Active Weight relative to the Index. Source: Dundas Global Investors and Apostle Funds Management as at 31/12/25

## Performance and Portfolio Comment

### Market overview

Global equities finished 2025 with gains amid year-end volatility and shifting monetary policy expectations. Broad benchmarks showed resilience, supported by healthy corporate earnings, AI-driven tech advances, and easing macro risks, though trading in December itself was mixed with days of weakness around key data and rate decisions. International stocks outperformed US equities in 2025, supported by a weaker US dollar and robust emerging market returns. Precious metals also rallied, reflecting safe-haven demand. Diverging central bank paths—Fed cuts versus steady ECB/BoE—added nuance to equity performance across regions, leading to rotation into non-US stocks and cyclicals late in the year.

In the United States, equity markets delivered another strong year, though December was choppy as investors digested Fed policy shifts. Major indices such as the S&P 500, Dow Jones, and Nasdaq recorded solid gains in 2025 with notable contributions from technology and AI-linked names. However, mid-December sessions saw broad declines, particularly in tech and semiconductors, as markets adjusted to monetary policy data and rate cut expectations. The S&P 500's year-end performance continued a rare multi-year streak of double-digit returns, even as the pace of gains slowed toward month end. Rotation and sector leadership shifts characterised the final weeks of trading.

European equities demonstrated strong performance in 2025 and maintained relative strength through December. Major indices like the FTSE 100 and Stoxx Europe 600 posted significant annual gains, with the FTSE 100 achieving its best year since 2009. Defensive and commodity-linked sectors helped buoy markets amid geopolitical tensions and fiscal stimulus in parts of the region. Eurozone inflation cooled toward target levels, reducing interest rate risk and supporting equity valuations. European markets benefited from improving macro data and preserved investor confidence into year-end.

Asian stock markets saw a mixed but generally positive finish to 2025. Major benchmarks such as Japan's Nikkei 225, Shanghai Composite, and Hang Seng exhibited modest upside into year-end, often reacting to US rate-cut expectations and local monetary policy dynamics. South Korea's equities and certain emerging Asian markets outperformed amid robust domestic growth and tech sector strength. Some sessions experienced volatility linked to external macro cues, but broader sentiment leaned supportive as markets shrugged off earlier sell-offs and geopolitical concerns. Overall, Asian equities closed the year with relatively strong performance, underpinned by favourable earnings outlooks and capital inflows.

### Performance overview

Over the past 12 months, the Fund has posted a total return net of fees of 3.50%, while the market returned 14.08%\*. In December, the Fund returned -1.24% net of fees underperforming the market by 0.58%.

Positive contributions came from the Fund's holdings in the IT, Financials and Consumer Discretionary sectors, as well as having no exposure to Utilities.

Fund performance was negatively impacted by holdings in the Financials and the Materials sectors. The Fund's overweight to Health Care and holdings within the sector also weighed on performance.

Regionally, North America and Asia Pacific were positive to performance, Fund holdings in Europe detracted.

The top five contributors were Booking Holdings, Nasdaq, TSMC, Salesforce and DBS Group.

The bottom five contributors were EssilorLuxottica, WR Berkley, Amphenol, Resmed and Strkyer.

### Dividends

The monthly average dividend increase was 11.2% and the announcements consisted of :- Mastercard 14.5%, Abbot Laboratories 6.8%, Zoetis 6.0%, and Stryker 4.8%.

### Portfolio changes

During the month, there were no new investments, and the Swedish multinational industrial technology company Hexagon was sold.

\*Solactive GBS Global Markets ex Australia Large & Mid Cap AUD Index.


## Contact us

### Apostle Funds Management Pty Ltd

Suite 2, Level 26, 6 O'Connell Street Sydney NSW 2000  
T: +61 2 8278 9554 F: +61 2 9247 9976  
www.apostlefm.com.au  
apostleclientservice@apostlefm.com.au

### K2 Asset Management Ltd

Level 44, 101 Collins Street Melbourne VIC 3000  
T: +61 3 9691 6111  
www.k2am.com.au



This document has been prepared by Apostle Funds Management Pty Limited ("Apostle") (ABN 16 129 922 612) (AFSL No. 458375). The Apostle Dundas Global Equity Fund (ARSN 093 116 771) is issued by K2 Asset Management Ltd ("K2") (ABN 95 085 445 094) (AFSL No. 244393), a wholly owned subsidiary of K2 Asset Management Holdings Limited (ABN 59 124 636 782). This material and the content of any offer document for the investment are principally governed by Australian rather than New Zealand law. This material may contain information provided directly by third parties which include Dundas Partners, LLP (AFSL No. 527238).

This material is for information purposes only. Offers to invest will only be made in the product disclosure statement ("PDS") and this material is not intended to substitute the PDS which outlines the risks involved and other relevant information. You should also consider the Target Market Determination ("TMD") when ascertaining if the product is appropriate for your needs. Both the PDS and the TMD are available from <https://www.k2am.com.au/forms-apostle- Dundas>. It is not an offer or a recommendation to invest and it should not be relied upon by investors in making an investment decision. Offers to invest will only be made in the relevant offer document and this material is not intended to substitute suitable disclosure documents which will outline the risks involved and other relevant information. Any investment carries potential risks and fees which are described in the relevant offer document. An investor should, before deciding whether to invest, consider the appropriateness of the investment, having regard to both the relevant offer document in its entirety and the investor's objectives, financial situation and need. This information has not been prepared taking into account your objectives, financial situation or needs. Please note that past investment performance is not a reliable indicator of future investment performance. No representation is made as to future performance or volatility of the investment. In particular, there is no guarantee that the investment objectives and investment strategy set out in this presentation may be successful. Any forward-looking statements, opinions and estimates provided in this material are based on assumptions and contingencies which are subject to change without notice and should not be relied upon as an indication of the future performance. Persons should rely solely upon their own investigations in respect of the subject matter discussed in this material. No representations or warranties, expressed or implied, are made as to the accuracy or completeness of the information, opinions and conclusions contained in this material. In preparing these materials, we have relied upon and assumed, without independent verification, the accuracy and completeness of all information available to Apostle. To the maximum extent permitted by law, all liability in reliance on this material is expressly disclaimed.

This document is strictly confidential and is intended solely for the use of the person to whom it has been delivered. It may not be reproduced, distributed or published, in whole or in part, without the prior approval of Apostle. Third party distributors may be used to market the investment to New Zealand investors. Where this occurs, this material can only be provided to New Zealand persons that the New Zealand distributor is authorised to deal with under New Zealand law and is not available to any person to whom it would be unlawful to make such offer or invitation.

The rating published on 05/2024 for the Apostle Dundas Global Equity Fund is issued by Lonsec Research Pty Ltd ABN 11 151 658 561 AFSL 421 445 (Lonsec Research). Ratings are general advice only and have been prepared without taking account of investors' objectives, financial situation or needs. Consider your personal circumstances, read the product disclosure statement and seek independent financial advice before investing. The rating is not a recommendation to purchase, sell or hold any product. Past performance information is not indicative of future performance. Ratings are subject to change without notice and Lonsec Research assumes no obligation to update. Lonsec Research uses objective criteria and receives a fee from the Fund Manager. Visit [lonsec.com.au](https://lonsec.com.au) for ratings information and to access the full report. © 2025 Lonsec. All rights reserved.

...